Fusion Pharmaceuticals Inc. has officially filed a Form S-1 registration statement with the Securities and Exchange Commission (SEC) for an initial public offering of its common shares with pricing to be determined. The company listed US $100 million as the proposed maximum aggregate offering for the purpose of calculating filing fees.
Fusion Pharmaceuticals had previously filed a confidential draft registration statement with SEC on April 3, 2020.
Fusion Pharmaceuticals has applied to list its common shares on The Nasdaq Global Market under the symbol “FUSN.”
Hamilton, Ontario based Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Its Targeted Alpha Therapies, or TAT, platform together with its proprietary Fast-Clear linker technology enable the company to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors.
Fusion Pharmaceuticals is backed HealthCap Advisor AB, Adams Street Partners, LLC, Johnson & Johnson Innovation – JJDC, Inc., TPG Global, LLC, Varian Medical Systems, Inc., Seroba Life Sciences Management Limited, Genesys Capital, Canada Pension Plan Investment Board (CPP Investments), OrbiMed Advisors LLC, FACIT Inc., Perceptive Advisors LLC, Pivotal bioVenture Partners LLC, and Rock Springs Capital LLC.
Founded in 2014, Fusion Pharmaceuticals has raised US $172.2 million from its backers.
Major shareholders, holing over 5% of pre-IPO shares, include HealthCap Advisor AB (12.56%), Adams Street Partners (12.33%), Varian Medical Systems, Inc. (11.33%), Johnson & Johnson Innovation – JJDC, Inc. (10.37%), CPP Investments (8.48%), TPG Global (8.11%), OrbiMed (7.84%), and Seroba Life Sciences (6.49%).
Fusion Pharmaceuticals is the second notable Canadian biotech company that has filed for IPO on NASDAQ.
On May 29, 2020, Repare Therapeutics Inc., a St-Laurent, Québe based precision oncology company, officially filed for IPO to list its shares on NASDAQ with the proposed symbol “RPTX”.
Repare Therapeutics had filed a confidential draft registration statement also on April 3, 2020.